BrainsWay Ltd
Company Profile
Business description
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Contact
16 Hartum Street
14th Floor, RAD Tower
Har HaHotzvim
Jerusalem9777516
ISRT: +972 25824030
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
120
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.20 | 113.70 | 1.29% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,367.08 | 1,638.36 | 3.11% |
| NZX 50 Index | 13,196.36 | 97.53 | 0.74% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,728.70 | 126.40 | 1.47% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |